- Deal broadens DiscernDx’s product portfolio and expands company’s role in metabolic diseases
- Will create novel precision medicine solutions for patients with NASH, the most severe form of nonalcoholic fatty liver disease
PALO ALTO, Calif.–(BUSINESS WIRE)–DiscernDx, today announced the expansion of the company’s precision medicine solutions with the acquisition of Luminist Labs, a privately-held novel diagnostic platform company for the early detection and diagnosis of liver disease. The acquisition will be integrated into the DiscernDx multi-omics platform to develop a deeper understanding of chronic metabolic diseases and create new precision medicine paradigms for physicians and patients. From the earliest indicators of developing diseases to existing conditions, the DiscernDx platform can see issues arising and deliver data to empower critical decision making and interventions.
Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease in the United States, affecting an estimated 100 million Americans, with over 3 million patients having the most severe form, nonalcoholic steatohepatitis (NASH). NAFLD is a disease with significant unmet medical need that is affecting millions of patients globally. There are currently no approved therapeutics in the US, with more than 250 active clinical trials. The current diagnostic and prognostic gold standard is a liver biopsy – a painful, costly and invasive option for patients. There is a clear need for a scalable, non-invasive test to support the accurate identification and management of NASH patients.
“This acquisition builds on DiscernDx precision medicine solutions and is a natural extension of our patient offering. Backed by over ten years of engineering, our platform measures and interprets the dynamic changes in our bodies to provide personalized health insights,” said Bruce Wilcox, CEO & co-founder at DiscernDx. “Our team will continue expanding our system, to create precision medicine solutions for the 1 in 2 Americans living with chronic metabolic diseases. The application of our proprietary multi-omics platform to the unique sample and data set created by Luminist Labs is expected to result in novel non-invasive diagnostic & prognostic solutions for patients living with NASH.”
“This acquisition is a significant milestone for Luminist Labs, as DiscernDx has the capabilities, scientific expertise and team to transform the biochemical data we’ve collected into vital health information to improve the lives of patients suffering from chronic liver diseases,” said Storm Stillman, CEO & co-founder at Luminist Labs.
Terms of the deal were not disclosed.
About DiscernDx
At DiscernDx, we believe in the promise of precision medicine and we are working to make that promise a reality. Our solutions will enable regular health monitoring, early disease detection, and personalized care for every individual, improving lives and transforming healthcare along the way. Our mission is to empower everyone with access to individualized clinical and molecular data to proactively manage and make informed decisions about their health. We are transforming how we see, think, and interact with our health. For more information visit www.discerndx.com.
Contacts
KKH Advisors
Kimberly Ha
kimberly.ha@kkhadvisors.com
917-291-5744
